JNJ CFO Joe Wolk: Manageable Downside Risks from Talc Lawsuits and Stelara Generic Competition
Johnson & Johnson Faces Challenges Yet Remains Optimistic for Growth Johnson & Johnson’s (JNJ) stock experienced a noticeable decline of over 3% on Wednesday morning, landing at approximately $143 per share. This drop comes despite … Read more